Although data are still controversial, considering its beneficial effects on insulin resistance, inflammation, oxidative stress, and fibrosis, the administration of exogenous GH and especially IGF-1 has a strong rationale and potential clinical applications in the treatment of NAFLD secondary to hypothalamic–pituitary dysfunction(s). The gene discussed is GH1; the disease is metabolic dysfunction-associated steatotic liver disease.